In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Bard buys Edwards's LifeStent for $74mm

Executive Summary

CR Bard (vascular, urological, cancer, and surgical devices) has purchased cardiovascular-focused Edwards Lifesciences's LifeStent product line for $74mm in cash. It may also pay $65mm upon approval for a superficial femoral artery indication ($50mm) and for the transfer of the device manufacturing ($15mm).

Deal Industry
  • Medical Devices
  • Medical Devices
    • Implantable Devices
    • Surgical Equipment & Devices
      • Minimally or Less Invasive
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Contract
    • Marketing (Licensing)
    • Product Purchase

Related Companies